Plain-English translation of NCT07221500 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for people with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to treatment. Unlike older treatments that block a protein called BTK, this medication completely destroys the BTK protein, which may work better for patients who have already tried other approaches. The study will look at whether the medication works, how safe it is, and whether people can take it long-term.
Many patients with this type of blood cancer eventually stop responding to current treatments like BTK inhibitors and BCL-2 inhibitors. This trial exists to see whether a completely different approach—destroying the BTK protein rather than just blocking it—might help people whose cancer has become resistant to standard options.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth on a regular schedule while doctors monitor your health with regular blood tests, scans, and check-ups. You will continue taking the treatment as long as it is helping and you are tolerating it well. If your cancer stops responding or you experience side effects that require stopping, you will transition to follow-up visits where doctors will continue monitoring your health even after you stop taking the medication.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States